Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Growth in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 200,600 shares, a growth of 49.3% from the September 15th total of 134,400 shares. Based on an average daily volume of 345,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 6.1% of the shares of the company are sold short.

Biofrontera Trading Up 13.3 %

Shares of NASDAQ:BFRI traded up $0.09 during midday trading on Friday, hitting $0.80. The stock had a trading volume of 115,406 shares, compared to its average volume of 389,039. Biofrontera has a 1 year low of $0.61 and a 1 year high of $8.20. The stock has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.24. The company has a market capitalization of $4.07 million, a PE ratio of -0.06 and a beta of 0.50.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.07. The company had revenue of $7.84 million for the quarter, compared to analyst estimates of $9.02 million. Biofrontera had a negative return on equity of 837.97% and a negative net margin of 38.34%. As a group, equities analysts expect that Biofrontera will post -3.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Benchmark restated a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research note on Friday, August 16th.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.